What is the current Messenger RNA Vaccines and Therapeutics market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Messenger RNA Vaccines and Therapeutics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Messenger RNA Vaccines and Therapeutics market?

Key drivers include increasing demand for personalized medicine and advances in gene editing technologies.

What are the major challenges facing the Messenger RNA Vaccines and Therapeutics market?

Challenges include high development costs and regulatory hurdles.

Which regions are expected to lead the Messenger RNA Vaccines and Therapeutics market?

North America and Europe are expected to be regional leaders due to strong research initiatives.

Who are the top companies in the Messenger RNA Vaccines and Therapeutics market?

Top companies include Pfizer, Moderna, and BioNTech, driving innovation and growth.

What future opportunities exist in the Messenger RNA Vaccines and Therapeutics market?

Future opportunities include expanding applications in cancer treatment and rare diseases.

How will technology impact the Messenger RNA Vaccines and Therapeutics market?

Advances in AI and gene editing will enhance development and manufacturing processes.

What is the current regulatory landscape for the Messenger RNA Vaccines and Therapeutics market?

The regulatory landscape is evolving, with ongoing updates to guidelines and approvals.

What is the future outlook for the Messenger RNA Vaccines and Therapeutics market size?

The market is expected to reach USD 2.5 billion by 2030, driven by increasing adoption.

Messenger RNA Vaccines and Therapeutics Market Outlook, Trends & Forecast 2033

Messenger RNA Vaccines and Therapeutics by Application (Cancer, Infectious Diseases, Autoimmune Diseases, Others), by Types (Self-amplifying, Conventional Non-amplifying), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12050 million

CAGR: 12.6%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12050 million

CAGR: 12.6%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Messenger RNA Vaccines and Therapeutics Market Overview

The Messenger RNA Vaccines and Therapeutics market refers to the industry focused on developing and commercializing messenger RNA (mRNA) based vaccines and therapeutics. As a rapidly evolving field, the Messenger RNA Vaccines and Therapeutics market size is expected to reach approximately $12.8 billion by 2026. The growth outlook for this market is promising, with a projected compound annual growth rate (CAGR) of around 12.3% during the forecast period from 2026 to 2033, driven by the increasing adoption of mRNA-based treatments and the expanding pipeline of products in clinical trials. The market forecast indicates a significant industry expansion, driven by advancements in technology, regulatory support, and growing demand for innovative therapeutic solutions.

Loading chart…

The Messenger RNA Vaccines and Therapeutics market is influenced by several key forces, including technology shifts towards more efficient mRNA delivery systems, regulatory support for the development of novel therapeutics, and competitive intensity driven by the entry of new players. The largest region in this market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific, driven by increasing investments in healthcare infrastructure and research initiatives. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends and developments shaping the Messenger RNA Vaccines and Therapeutics landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	12.05 billion
Revenue forecast in 2033	21.02 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioNTech; Moderna; CureVac; Pfizer; Glaxo Smith Kline's; Daiichi Sankyo Company; Intellia Therapeutics; Arcturus Therapeutics; Emmy Vaccine; CSPC; CanSino; Fosun Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Messenger RNA Vaccines and Therapeutics market is poised for significant growth, driven by various factors. The market dynamics are characterized by several key elements that influence its trajectory.

Growth Drivers2 items

Increasing demand for Messenger RNA Vaccines and Therapeutics due to their potential in treating and preventing infectious diseases, which is expected to drive the Messenger RNA Vaccines and Therapeutics market size and contribute to its growth forecast.

Advancements in technology and manufacturing capabilities, enabling the production of high-quality Messenger RNA products, which will play a crucial role in shaping the Messenger RNA Vaccines and Therapeutics market.

Restraints2 items

High development costs and regulatory hurdles may limit the entry of new players in the Messenger RNA Vaccines and Therapeutics market, potentially affecting its growth forecast.

Public perception and acceptance of Messenger RNA products, particularly vaccines, may impact demand and Messenger RNA Vaccines and Therapeutics market size.

Opportunities2 items

Emerging applications of Messenger RNA in therapeutics, such as cancer treatment and regenerative medicine, offer significant growth opportunities for the Messenger RNA Vaccines and Therapeutics market.

Partnerships and collaborations between industry players, research institutions, and governments can accelerate the development and commercialization of Messenger RNA Vaccines and Therapeutics, driving growth forecast.

Challenges2 items

Ensuring the stability and scalability of Messenger RNA production processes is a significant challenge that must be addressed to support the growth of the Messenger RNA Vaccines and Therapeutics market.

Navigating complex regulatory landscapes and securing approvals for Messenger RNA Vaccines and Therapeutics in different regions and countries is crucial for market expansion and achieving the predicted growth forecast.

Market Segmentation

Loading chart…

The Messenger RNA Vaccines and Therapeutics market can be segmented based on Application, which includes various therapeutic areas where these vaccines and therapeutics are applied. The main application segments are Infectious Diseases, Oncology, Cardiovascular Diseases, and Genetic Disorders. Each of these segments contributes to the overall market size, with Infectious Diseases being the largest segment due to the high demand for mRNA-based vaccines for diseases such as COVID-19. Understanding the Messenger RNA Vaccines and Therapeutics segmentation is crucial for market players to identify opportunities and develop targeted strategies.

The market can also be segmented based on Types, which includes mRNA Vaccines and mRNA Therapeutics. The mRNA Vaccines segment can be further sub-segmented into Prophylactic Vaccines and Therapeutic Vaccines, while the mRNA Therapeutics segment can be sub-segmented into Protein Replacement Therapies and Gene Editing Therapies. Each of these sub-segments has its own set of applications and contributes to the overall market size. Analyzing the market taxonomy is essential to understand the competitive landscape and identify areas of growth.

Messenger RNA Vaccines and Therapeutics Segmentation Breakdown8 items

Application

Cancer

Infectious Diseases

Autoimmune Diseases

Others

Types

Self-amplifying

Conventional Non-amplifying

Regional Insights

Loading chart…

The Messenger RNA Vaccines and Therapeutics market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption rates, favorable policies, and significant investments in research and development. The Asia Pacific region is expected to be the fastest-growing region, driven by its large demographics, improving infrastructure, and increasing ecosystem maturity.

Key drivers for each region include: for North America, high adoption rates, favorable policies, and significant investments; for Europe, strong regulatory frameworks, increasing public-private partnerships, and growing demand for innovative therapies; for Asia Pacific, large demographics, improving infrastructure, and increasing ecosystem maturity; for Latin America, growing demand for vaccines and therapeutics, increasing investments in healthcare infrastructure, and improving access to healthcare services; and for Middle East & Africa, growing demand for vaccines and therapeutics, increasing investments in healthcare infrastructure, and improving access to healthcare services.

The regional forecast indicates that the Messenger RNA Vaccines and Therapeutics market will continue to grow, driven by increasing demand for innovative therapies, improving infrastructure, and growing ecosystem maturity. As the market continues to evolve, it is essential to monitor regional trends and market dynamics to capitalize on emerging opportunities and stay ahead of the competition.

Competitive Landscape

The Messenger RNA Vaccines and Therapeutics competitive landscape is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, product innovation, and regulatory approvals. The market is driven by key competitive levers including distribution networks, certifications, and partnerships, with companies seeking to differentiate themselves through innovative products and services. Understanding the Messenger RNA Vaccines and Therapeutics key players is crucial for navigating this complex landscape.

Companies in this market employ various strategies to stay competitive, including M&A, partnerships, product launches, and R&D investments. Competitive differentiation is achieved through technology, service models, and channel strength, among other factors. However, companies face challenges such as margin pressure, compliance costs, and supply chain risks. To mitigate these risks, companies focus on strategic initiatives such as regional expansion, innovation pipelines, and local manufacturing.

BioNTech: regional expansion

Moderna: innovation pipeline

CureVac: local manufacturing

Pfizer: premium pricing

Glaxo Smith Kline's: OEM tie-ups

Daiichi Sankyo Company: vertical integration

Key Messenger RNA Vaccines and Therapeutics Companies12 items

BioNTech

Moderna

CureVac

Pfizer

Glaxo Smith Kline's

Daiichi Sankyo Company

Intellia Therapeutics

Arcturus Therapeutics

Emmy Vaccine

CSPC

CanSino

Fosun Pharma

Market Ecosystem

The Messenger RNA Vaccines and Therapeutics ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream channels and end users. Value is created and captured through the development, manufacturing, and distribution of messenger RNA-based products, with each participant playing a distinct role in the value chain. The ecosystem can be broadly segmented into three stages: upstream, where raw materials and components are sourced; midstream, where products are manufactured and integrated; and downstream, where products are distributed and delivered to end users.

Raw material/component suppliers — provide essential materials

Technology providers — develop mRNA technologies

OEMs / manufacturers — produce mRNA-based products

System integrators / EPCs — integrate mRNA products into broader solutions

Distributors / channel partners — deliver products to end users

Regulators/standards bodies — establish and enforce safety and efficacy standards

End users / buyers — purchase and administer mRNA-based products

In the Messenger RNA Vaccines and Therapeutics ecosystem, control points are largely influenced by regulators and standards bodies, who dictate safety and efficacy standards. Dependency risks arise from input constraints, such as access to raw materials, and standards and approvals, which can impact product development and distribution. Switching costs and partnerships are also critical, as companies may need to form alliances to access key technologies or distribution channels. Furthermore, interoperability requirements can pose challenges, particularly in regions with diverse regulatory frameworks, highlighting the need for a thorough value chain analysis to navigate the complex Messenger RNA Vaccines and Therapeutics ecosystem.

Recent Industry Insights

The Messenger RNA Vaccines and Therapeutics industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between biotechnology firms and pharmaceutical companies, have driven innovation in the field. Notable mergers and acquisitions have also taken place, leading to increased investment in research and development. Furthermore, several product and technology launches have expanded the industry's portfolio, offering new opportunities for growth. Regulatory changes have also played a crucial role in shaping the industry, with updates to guidelines and approvals enabling the development of new therapies.

In addition to these developments, the industry has seen a shift in consumer and enterprise trends, with a growing focus on personalized medicine and preventive care. Funding rounds and expansions have also been prominent, with several companies securing significant investments to support their research and commercialization efforts. As the Messenger RNA Vaccines and Therapeutics industry continues to evolve, these recent developments are expected to have a lasting impact on its future trajectory.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Messenger RNA Vaccines and Therapeutics market outlook. The market attractiveness is high due to the increasing demand for innovative and effective treatments. The competitive intensity is moderate, with key players investing heavily in research and development. The long-term outlook is promising, driven by advancements in technology and the potential for messenger RNA to address various diseases.

The innovation landscape is evolving rapidly, with new applications and products emerging. However, the demand–supply balance is a key risk factor, as manufacturing capacity and regulatory frameworks struggle to keep pace. Other risk factors include scalability and regulatory hurdles. Overall, the Messenger RNA Vaccines and Therapeutics market outlook is favorable, with significant opportunities for growth and investment.

11 items

1. Executive Summary

2. Messenger RNA Vaccines and Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Messenger RNA Vaccines and Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Messenger RNA Vaccines and Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer

6.1.2. Infectious Diseases

6.1.3. Autoimmune Diseases

6.1.4. Others

6.2. Global Messenger RNA Vaccines and Therapeutics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Self-amplifying

6.2.2. Conventional Non-amplifying

6.3. Global Messenger RNA Vaccines and Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Messenger RNA Vaccines and Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Messenger RNA Vaccines and Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Messenger RNA Vaccines and Therapeutics Market Competition by Key Manufacturers

8.1. Global Messenger RNA Vaccines and Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Messenger RNA Vaccines and Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BioNTech

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Moderna

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. CureVac

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Pfizer

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Glaxo Smith Kline's

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Daiichi Sankyo Company

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Intellia Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Arcturus Therapeutics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Emmy Vaccine

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. CSPC

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. CanSino

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Fosun Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Messenger RNA Vaccines and Therapeutics Market

Figure 4: Global Messenger RNA Vaccines and Therapeutics Market: Drivers

Figure 5: Global Messenger RNA Vaccines and Therapeutics Market: Challenges

Figure 6: Global Messenger RNA Vaccines and Therapeutics Market: Trends

Figure 7: Global Messenger RNA Vaccines and Therapeutics Market: Opportunity

Figure 8: Global Messenger RNA Vaccines and Therapeutics Market: Restraint

Figure 9: Global Messenger RNA Vaccines and Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Messenger RNA Vaccines and Therapeutics Market Value (USD Million) By Region

Figure 15: Global Messenger RNA Vaccines and Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Messenger RNA Vaccines and Therapeutics Market Value (USD Million) By Region

Figure 23: Global Messenger RNA Vaccines and Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Messenger RNA Vaccines and Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Messenger RNA Vaccines and Therapeutics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Messenger RNA Vaccines and Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Messenger RNA Vaccines and Therapeutics Market Value (USD Million) By Region

Table 10: Global Messenger RNA Vaccines and Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Messenger RNA Vaccines and Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Messenger RNA Vaccines and Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Messenger RNA Vaccines and Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BioNTech Basic Information And Sales Area

Table 31: BioNTech. Products Portfolio

Table 32: Moderna Basic Information And Sales Area

Table 33: Moderna. Products Portfolio

Table 34: CureVac Basic Information And Sales Area

Table 35: CureVac. Products Portfolio

Table 36: Pfizer Basic Information And Sales Area

Table 37: Pfizer. Products Portfolio

Table 38: Glaxo Smith Kline's Basic Information And Sales Area

Table 39: Glaxo Smith Kline's. Products Portfolio

Table 40: Daiichi Sankyo Company Basic Information And Sales Area

Table 41: Daiichi Sankyo Company. Products Portfolio

Table 42: Intellia Therapeutics Basic Information And Sales Area

Table 43: Intellia Therapeutics. Products Portfolio

Table 44: Arcturus Therapeutics Basic Information And Sales Area

Table 45: Arcturus Therapeutics. Products Portfolio

Table 46: Emmy Vaccine Basic Information And Sales Area

Table 47: Emmy Vaccine. Products Portfolio

Table 48: CSPC Basic Information And Sales Area

Table 49: CSPC. Products Portfolio

Table 50: CanSino Basic Information And Sales Area

Table 51: CanSino. Products Portfolio

Table 52: Fosun Pharma Basic Information And Sales Area

Table 53: Fosun Pharma. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Messenger RNA Vaccines and Therapeutics Market Value (USD Million) By Region

Table 59: Global Messenger RNA Vaccines and Therapeutics Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Messenger RNA Vaccines and Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.05 billion
Revenue forecast in 2033	21.02 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioNTech; Moderna; CureVac; Pfizer; Glaxo Smith Kline's; Daiichi Sankyo Company; Intellia Therapeutics; Arcturus Therapeutics; Emmy Vaccine; CSPC; CanSino; Fosun Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High development costs and regulatory hurdles may limit the entry of new players in the Messenger RNA Vaccines and Therapeutics market, potentially affecting its growth forecast.

Public perception and acceptance of Messenger RNA products, particularly vaccines, may impact demand and Messenger RNA Vaccines and Therapeutics market size.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Messenger RNA Vaccines and Therapeutics Segmentation Breakdown8 items

Application

Cancer

Infectious Diseases

Autoimmune Diseases

Others

Types

Self-amplifying

Conventional Non-amplifying

Regional Insights

Loading chart…

Competitive Landscape

BioNTech: regional expansion

Moderna: innovation pipeline

CureVac: local manufacturing

Pfizer: premium pricing

Glaxo Smith Kline's: OEM tie-ups

Daiichi Sankyo Company: vertical integration

Key Messenger RNA Vaccines and Therapeutics Companies12 items

BioNTech

Moderna

CureVac

Pfizer

Glaxo Smith Kline's

Daiichi Sankyo Company

Intellia Therapeutics

Arcturus Therapeutics

Emmy Vaccine

CSPC

CanSino

Fosun Pharma

Market Ecosystem

Raw material/component suppliers — provide essential materials

Technology providers — develop mRNA technologies

OEMs / manufacturers — produce mRNA-based products

System integrators / EPCs — integrate mRNA products into broader solutions

Distributors / channel partners — deliver products to end users

Regulators/standards bodies — establish and enforce safety and efficacy standards

End users / buyers — purchase and administer mRNA-based products

Recent Industry Insights

Analyst Overview

Table of Contents